CLINICAL TRIALS

MIBI Thyr (Not applicable)

Investigator physician: Pr Laurent BRUNEAU

Interest of the combination of ultrasound with Ti-RADS score / dual tracer MIBI-Tc99m/Iodine-123 scintigraphy in the detection of malignancy of thyroid nodules (≥ 15 mm) classified Bethesda III or IV in cytopuncture

Thyroid nodules (≥ 15 mm) classified as Bethesda III or IV on cytopuncture


The main objective of study is to show that the addition of ultrasound to MIBI/Iode-123 double isotope diagnostic scintigraphy increases (by at least 5%) the Negative Predictive Value (NPV) compared with scintigraphy alone, in the detection of malignancy of thyroid nodules ≥15 mm Bethesda III-IV in cytology.
The hypothesis is that MIBI/Iodine-123 scintigraphy has a VPN ≥90% for the detection of malignancy in a thyroid nodule, and that the addition of ultrasound (using recognized malignancy criteria) increases the VPN to 95%.


Imaging: SPECT/CT en 123Iode
Study status: Recruiting
Clinical Trial number: NCT03498183
Funding:

CHRU Nantes